Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia
- 9 May 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (9) , 1867-1875
- https://doi.org/10.1200/jco.2000.18.9.1867
Abstract
PURPOSE: To determine the remission rate and toxicity of mitoxantrone, etoposide, and cyclosporine (MEC) therapy, multidrug resistance-1 (MDR1) status, and steady-state cyclosporine (CSA) levels in children with relapsed and/or refractory acute myeloid leukemia. PATIENTS AND METHODS: MEC therapy consisted of mitoxantrone 6 mg/m2/d for 5 days, etoposide 60 mg/m2/d for 5 days, and CSA 10 mg/kg for 2 hours followed by 30 mg/kg/d as a continuous infusion for 98 hours. Because of pharmacokinetic interactions, drug doses were decreased to 60% of those found to be effective without coadministration of CSA. MDR1 expression was evaluated by reverse transcriptase polymerase chain reaction, flow cytometry, and the ability of CSA at 2.5 μmol/L to increase intracellular accumulation of 3H-daunomycin in blasts from bone marrow specimens. RESULTS: The remission rate was 35% (n = 23 of 66). Overall, 35% of patients (n = 23) achieved complete remission (CR), 12% of patients (n = 8) achieved partial remission, and 9% of patients (n = 6) died of infection. Exposure to CSA levels of greater than 2,400 ng/mL was achieved in 95% of patients (n = 56 of 59). Toxicities included infection, cardiotoxicity, myelosuppression, stomatitis, and reversible increases in serum creatinine and bilirubin. In most who had relapsed while receiving therapy or whose induction therapy had failed, response was not significantly different for MDR1-positive and MDR1-negative patients. CONCLUSION: Serum levels of CSA capable of reversing multidrug resistance are achievable in children with acceptable toxicity. The CR rate of 35% achieved in this study is comparable to previously reported results using standard doses of mitoxantrone and etoposide. The use of CSA may have improved the response rate for the MDR1-positive patients so that it was not different from that for the MDR1-negative patients.Keywords
This publication has 19 references indexed in Scilit:
- Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemiaLeukemia, 1998
- DIAGNOSIS AND TREATMENT OF CHILDHOOD ACUTE MYELOGENOUS LEUKEMIAPediatric Clinics of North America, 1997
- Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity.Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997
- Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemiaLeukemia, 1997
- Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in ChildhoodNew England Journal of Medicine, 1996
- Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833JNCI Journal of the National Cancer Institute, 1995
- Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.Journal of Clinical Oncology, 1993
- Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.Proceedings of the National Academy of Sciences, 1992
- Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.Proceedings of the National Academy of Sciences, 1990
- Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.Journal of Clinical Oncology, 1990